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Introduction: Pyogenic β-hemolytic streptococci (including Group A, C and 
G Streptococcus) are some of the most important Gram-positive bacterial pathogens in 
human medicine. Although effective therapy is available, invasive streptococcal infections 
are associated with a significant disease burden.
Methods: In this retrospective study, the epidemiological characteristics of invasive Group 
A (iGAS) and Group C and G (iGCGS) streptococci, along with tonsillo-pharyngitis-causing 
pGAS and pGCGS infections, were assessed in Southern Hungary. A total of 1554 cases of 
streptococcal tonsillo-pharyngitis infections (26.5–44.1/100,000 persons, pGAS: 95.5%; 
n=1484) and 1104 cases of invasive streptococcal infections were detected (12.5–31.4/ 
100,000 persons, iGAS: 77.9%; n=861).
Results: The average age of the affected patients in the various groups were the following: 
pGAS: 13.2±13.1 years, pGCGS: 21.0±15.0 years (p=0.039), iGAS: 49.1±12.8 years, iGCGS: 
58.7±18.5 years (p>0.05). iGAS isolates originated from abscesses (47.1%), blood culture 
samples (24.1%), surgical samples (16.7%), biopsies (4.6%), pleural fluid (3.5%), pus (2.0%), 
synovial fluid (1.3%) and cerebrospinal fluid samples (0.7%). In contrast, iGCGS isolates mainly 
originated from blood culture samples (53.8%), abscesses (22.9%), surgical samples (12.3%), 
synovial fluid (5.1%), pleural fluid (3.7%), pus (1.8%) and cerebrospinal fluid samples (0.4%). 
All respective isolates were susceptible to benzyl-penicillin; overall resistance levels for ery-
thromycin (10.5% for GAS, 21.4% for GCGS) and clindamycin (9.2% for GAS, 17.2% for 
GCGS) were significantly higher in GCGS isolates, while resistance levels for norfloxacin were 
higher in GAS isolates (13.5% for GAS, 6.9% for GCGS).
Conclusion: The rates of resistance to macrolides and clindamycin are a cause for concern 
(especially among GCGS isolates); however, resistance levels are still relatively low, com-
pared to Southern European countries.
Keywords: epidemiology, antibiotics, group A Streptococcus, group C Streptococcus, group 
G Streptococcus, Hungary, Streptococcus pyogenes, Streptococcus dysgalactiae subspecies 
equisimilis
Introduction
Pyogenic β-hemolytic streptococci (consisting of Streptococcus pyogenes [Group 
A Streptococcus; GAS], S. agalactiae [Group B Streptococcus], S. dysgalactiae 
subsp. equisimilis (SDSE; relevant in human disease) and S. dysgalactiae subsp. 
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dysgalactiae (SDSD; relevant in animal disease) [Group 
C and Group G Streptococcus; GCS and GGS]) are some 
of the most important Gram-positive bacterial pathogens 
in human medicine, especially in the paediatric 
population.1–5 Streptococci were classified according to 
the Lancefield-grouping, a system based on the composi-
tion of the cell wall antigens;6 although some believe that 
this classification has outlived its usefulness in the era of 
whole genome sequencing (WGS), Lancefield-grouping is 
still frequently used in routine clinical practice.7
GAS and GCS/GGS species are taxonomically very close, 
with a 72% sequence similarity; in addition, these bacteria 
share many virulence factors (eg, the M protein, encoded by 
the emm genes, surface proteins, fibronectin (Fn)-binding 
proteins, streptolysin S and streptolysin O).8–11 Due to their 
pronounced tissue tropism, GAS and GCS/GGS isolates 
frequently occur as colonizers of the skin, oropharynx, alimen-
tary tract and genito-urinary region.12 In fact, a recent meta- 
analysis has reported that the prevalence of GAS carriage in 
children was 12%, while other report concluded that GCS/ 
GGS carriage in all age groups was around 4%; however, 
carriage rates may vary greatly based on seasonality and 
different geographical regions.13,14 Nevertheless, they are 
also highly pathogenic, capable of causing a wide spectrum 
of illnesses, being an important factor of morbidity and 
mortality.15 Mild manifestations may include tonsillo- 
pharyngitis (“strep throat”), wound infections and 
impetigo,16 while severe infections, such as scarlet fever,17 
endophthalmitis,18 mastoiditis,19 septic arthritis,20 
osteomyelitis,21 necrotizing fasciitis,22 puerperal infections,23 
bacteremia and sepsis,24 meningitis,25 endocarditis,26 and 
streptococcal toxic shock syndrome (STSS)27 may also 
occur. In addition, clinicians must take into consideration the 
emergence of post-streptococcal manifestations, such as rheu-
matic fever, rheumatic heart disease, glomerulonephritis and 
other immune-mediated complications.28
Although effective therapy is available, invasive strep-
tococcal infections are associated with a significant dis-
ease burden, estimated at >500,000 worldwide deaths 
annually.29–32 In the United States, GAS is responsible 
for 1–2.5 million cases of tonsillo-pharyngitis, 12,000–-
25,000 invasive infections and around 1250–2000 deaths, 
according to the CDC database. While the importance of 
GAS in human infections is well-known, the importance 
of GCS/GGS species has only been studied extensively in 
recent times.33 This may be attributed to novel technical 
developments in clinical microbiology, in addition to the 
growing number of people in immunocompromised state, 
at higher risk for GCS/GGS infections.34 Several reports 
have highlighted the role of GCS/GGS in severe, invasive 
infections: in fact, GCS/GGS are responsible for 80% of 
invasive infections caused by non-GAS and non-GBS β- 
hemolytic streptococci, and in some countries, their inci-
dence approaches that of invasive GAS infections.35,36 
Many authors have also suggested the phenomenon of 
epidemiological differentiation between patients affected 
by GAS and GCS/GGS infections, ie, the incidence of 
GCS/GGS infections is reported to be higher among adult 
patients, both in tonsillo-pharyngitis and in invasive 
infections, and the resistance levels associated with 
GCS/GGS infections have also been reported to be 
higher.37,38
The long-term surveillance of streptococcal infections 
is important for clinical medicine and for public health 
purposes; however, the availability of reports from 
Hungary and Central/Eastern Europe is scarce. In the pre-
sent study, we report the epidemiological characteristics of 
pharyngitis and invasive infections caused by GAS and 
GCS/GGS in Southern Hungary over a 10-year surveil-
lance period (2008–2017).
Materials and Methods
Study Site and Population
The present retrospective study was carried out using 
epidemiological data/demographics and microbiological 
data collected between the period of 2008.01.01 and 
2017.12.31 at the Institute of Clinical Microbiology 
(University of Szeged). The Institute acts as the affiliated 
diagnostic laboratory for the Albert Szent-Györgyi 
Clinical Center (ASCC), the principal primary- and ter-
tiary-care teaching hospital in Southern Hungary and also 
receives microbiological samples from community-based 
healthcare-professionals in the region.39 The Clinical 
Center is equipped has a bed capacity of 1820 beds 
(1465 acute and 355 chronic beds, respectively), according 
to the data of the Hungarian National Health Insurance 
Fund (NEAK).40 The population of the region has 
decreased from 417,456 to 399,012 during the respective 
10-year period, based on Eurostat data for the region. As 
high as 27.5% of the population lives in rural areas, while 
the majority of the population lives in cities/towns.
Data Collection
Electronic search in the records of the MedBakter labora-
tory information system (LIS) for samples positive for 
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GAS, GCS and GGS was conducted by the authors (M.G., 
Á.M. and A.L.). Age and sex of the patients, date of 
sample submission, sample type and indication for sample 
submission (including preliminary diagnoses) were 
collected.39 During data analysis, affected patients were 
differentiated to two age groups: 0–17 year-olds and 18 
and over, based on Oppegaard et al.38 Retrospective chart 
review of the affected patients was not performed; there-
fore, the incidence of chronic sequelae such as acute 
rheumatic fever, rheumatic heart disease or poststreptococ-
cal glomerulonephritis was not assessed.41
Due to the very low number of group C streptococci and 
the fact that β-haemolytic group C and G streptococci caus-
ing human infections most frequently belong to the species 
SDSE, these bacteria were treated as one group (GCGS) for 
statistical purposes, based on Oppegaard et al.38 GAS and 
GCGS bacteria were categorized into two groups, namely 
tonsillo-pharyngitis-causing GAS/GCGS (pGAS and 
pGCGS) and GAS/GCGS causing invasive infections 
(iGAS and iGCGS). Cases of iGAS and iGCGS were 
defined as the isolation of a Group A or Group C/G 
Streptococcus from a sterile site (eg, blood, cerebrospinal 
fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgi-
cal aspirate, bone, joint fluid, or internal body site) or from 
a wound culture accompanied by necrotizing fasciitis (NF) 
or streptococcal toxic shock syndrome (STSS), based on the 
criteria established by Rudolph et al.41 Repeatedly positive 
cultures with the same organism identified within 30 days of 
initial isolation were considered to be from a single 
episode.41 Isolates considered as contaminants during 
microbiological analysis were excluded from the study. As 
an external control for our data, the incidence of scarlet 
fever (erythrogenic toxin-producing GAS; which is 
a reportable illness in Hungary) was collected from the 
National Bacteriological Surveillance database of the 
National Institute of Public Health (NNK) for the period 
of 2008–2017. Rates were expressed as x/100,000 persons.
Bacterial Identification
Processing of clinical samples submitted to the Institute of 
Clinical Microbiology was carried out according to guide-
lines for routine clinical bacteriology. Isolates were cul-
tured on Columbia agar plates containing 5% sheep blood 
(bioMérieux, Marcy-l’Étoile, France) and stored in Todd 
Hewitt broth (bioMérieux, Marcy-l’Étoile, France) with 
glycerol in a −80°C freezer. All isolates have initially 
been identified based on macroscopic appearance after 24 
h (β-hemolysis, colony size), Gram-staining results and 
bacitracin sensitivity, which was followed-up by hippurate 
test, pyrrolidonylarylamidase (PYR) test (Remel, Lenexa, 
KS, USA) and slide agglutination test kit for Lancefield 
antigen grouping (Slidex Strepto-Kit, bioMerieux, Marcy- 
l’Étoile, France).38,41 After 2013, this was complemented 
by matrix-assisted laser desorption/ionization time-of- 
flight mass spectrometry (MALDI-TOF MS; Bruker 
Daltonics, Bremen, Germany). The methodology of sam-
ple preparation and the technical details for MALDI-TOF 
MS measurements were described elsewhere.42,43 The 
MALDI Biotyper RTC 3.1 software (Bruker Daltonics, 
Germany) and the MALDI Biotyper Library 3.1 were 
used for spectrum analysis. Identification was considered 
reliable on species-level, if the log(score) values were 
≥2.300. If there was a discrepancy between the identifica-
tion and the agglutination test results, the identification 
results were taken into consideration (ie, irrespective of 
the outcome of the agglutination test, if an isolate was 
identified as S. pyogenes, it was grouped as GAS, and if an 
isolate was identified as S. dysgalactiae subsp. equisimilis, 
it was grouped as GCGS).
Antibiotic Susceptibility Testing
Antimicrobial susceptibility testing (AST) was performed 
using the Kirby–Bauer disk diffusion method (Liofilchem, 
Abruzzo, Italy) on Mueller–Hinton agar plates comple-
mented with 5% defibrinated horse blood and 20 mg/L β- 
NAD (MH-F), based on EUCAST laboratory standards.44 
The following antibiotic disks were used: benzyl-penicillin 
(1 IU; susceptibility to β-lactams was inferred from this 
test), erythromycin (15 µg), clindamycin (2 µg), norflox-
acin (10 µg; susceptibility to quinolones was inferred from 
this test), trimethoprim-sulfamethoxazole (1.25–23.75 µg), 
tetracycline (30 µg), vancomycin (5 µg) and linezolid (10 
µg). Inducible clindamycin resistance was detected using 
the erythromycin-clindamycin D test; these strains were 
also reported as resistant to clindamycin. Interpretation of 
results was carried out using EUCAST clinical 
breakpoints.44 During data analysis, intermediately suscep-
tible results were grouped with and reported as resistant. 
Streptococcus pneumoniae ATCC 49619 was used as 
a quality control strain.
Statistical Analysis
Statistical analyses, including the descriptive analysis 
(means or medians with ranges and percentages to char-
acterize data) and statistical tests (Χ2-tests) were per-
formed with IBM SPSS Statistics for Windows 24.0 
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(IBM Corp., Armonk, NY, USA). P values <0.05 were 
considered statistically significant.
Ethical Considerations
Our research complies with the Declaration of Helsinki 
(1964) and its amendments. The study was deemed exempt 
from ethics review by the Institutional Review Board of the 
University of Szeged, as anonymity and the privacy of the 
patients was maintained during data collection and the col-
lected data were handled confidentially. Informed consent 
was not required due to the retrospective nature of the 
review. Data on the epidemiology of scarlet fever were 
freely available from the National Bacteriological 
Surveillance database of the National Institute of Public 
Health; therefore, no approval was required for their use.
Results
Epidemiology of GAS/GCGS Isolates 
Throughout the Study Period
Over the 10-year study period (January 2008 through 
December 2017), 1554 cases of streptococcal tonsillo- 
pharyngitis and 1104 cases of invasive streptococcal 
infections were detected (Table 1). Tonsillo-pharyngitis 
cases were predominantly caused by GAS (95.5%; n=1484), 
with 148.4±31.9 cases/year (ranging between 108 cases, ie, 
26.5/100,000 persons in 2009, and 216 cases, ie, 44.1/ 
100,000 persons in 2010), GCGS corresponded to 
a minority of pharyngitis cases (4.5%; n=70), with 8.0±3.6 
cases/year (ranging between 1 case, ie, 0.2/100,000 persons in 
2011, and 12 cases, ie, 2.9/100,000 cases in 2012). Similarly, 
GAS were the more common pathogens in invasive infections 
as well; however, their dominance was not as pronounced as 
in pharyngitis. GAS isolates constituted 77.9% (n=861), with 
84.0±26.5 cases/year (ranging between 51 cases, ie, 12.5/ 
100,000 persons in 2016, and 128 cases, ie, 31.4/100,000 per-
sons in 2011). GCGS isolates were relevant in 22.1% (n=243) 
of cases, with 22.6±18.9 cases/year (ranging between 3 cases, 
ie, 0.73/100,000 persons in 2010, and 50 cases, ie, 12.3/ 
100,000 persons in 2014) (Table 1). The annual distribution 
of GAS/GCGS isolates causing tonsillo-pharyngitis and inva-
sive infections is presented in Figures 1–4. The incidence and 
rate of pGAS and pGCGS isolates was relatively constant 
between 2012 and 2017 (Figures 1 and 2). The incidence of 
iGAS reached a peak in 2011, while a steady decrease was 
Table 1 Epidemiology, Age and Gender-Distribution of Group A and Group C/G Streptococcal Infections Causing Pharyngitis and 
Invasive Infections, 2008–2017
Factor Group iGAS iGCGS Sum Statistics*
Study years Overall N=861 N=243 N=1104
2008–2012 517 (91.1%) 50 (8.9%) 567 (100%) p<0.0001 
(Χ2=26.29, DOF: 1)2013–2017 344 (65.3%) 193 (34.7%) 537 (100%)
Age group Overall N=861 N=243 N=1104
0–17 years 54 (37.2%) 91 (62.8%) 145 (100%) p<0.0001 (Χ2=161.46, DOF: 1)
18 years and older 807 (84.1%) 152 (15.9%) 959 (100%)
Sex (all ages) Overall N=861 N=243 N=1104
Male 536 (78.7%) 145 (21.3%) 681 (100%) p>0.05 
(Χ2=0.53, DOF: 1)Female 325 (76.8%) 98 (23.2%) 423 (100%)
Factor Group pGAS pGCGS Overall Statistics*
Study years Overall N=1484 N=70 N=1554
2008–2012 788 (95.9%) 23 (4.1%) 811 (100%) p=0.039 
(Χ2=4.27, DOF: 1)2013–2017 696 (93.7%) 47 (6.3%) 743 (100%)
Age group Overall N=1484 N=70 N=1554
0–17 years 1172 (96.7%) 40 (3.3%) 1212 (100%) p<0.0001 
(Χ2=18.56, DOF: 1)18 years and older 312 (91.2%) 30 (8.8%) 342 (100%)
Sex (all ages) Overall N=1484 N=70 N=1554
Male 808 (96.9%) 25 (3.1%) 833 (100%) p=0.002 
(Χ2=9.43, DOF: 1)Female 676 (93.8%) 45 (6.2%) 721 (100%)
Note: *Statistical comparison of the two sub-groups (study years, age groups and sex). 
Abbreviation: DOF, degrees of freedom.
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seen, beginning from 2012 (Figure 3); on the other hand, the 
incidence of iGCGS isolates increased continuously through-
out the study period (Figure 4) pGCGS and iGCGS isolates 
were statistically more common in the second half (2013–-
2017) of the study period. Statistically significant differences 
were observed based on sex (pGCGS were more frequent in 
females) and age (pGCGS were more frequent in patients 
aged 0–17 years) (Table 1).
Seasonal variation was observed in the incidence of 
both types of streptococcal infections: pGAS was most 
common in the period between December and February 
(35.0%), while the peak of pGCGS was seen a bit later, 
between January and March (29.5%). Peak incidence of 
iGAS infections were also detected between December 
and February (31.7%), with a smaller peak during summer 
months (June–August; 18.4%). In contrast, the incidence 
of iGCGS showed a peak during summer months (June– 
August; 33.2%), while a winter peak was not observed. To 
put our local results in a national context, the incidence of 
GAS and GCGS infections was compared to the incidence 
of scarlet fever between 2008 and 2017: the average num-
ber of scarlet fever cases in Hungary was 2972.2±617.2/ 
year (ranging between 2356 cases, ie, 24.1/100,000 persons 
in 2009, and 4411 cases, ie, 45.1/100,000 persons in 
2017).
The average age of the affected patients in the various 
groups was the following: pGAS: 13.2±13.1 years and 
pGCGS: 21.0±15.0 years (p=0.039), iGAS: 49.1±12.8 
years and iGCGS: 58.7±18.5 years (p>0.05). The distribu-
tion of GAS/GCGS isolates causing pharyngitis and inva-
sive infections among patients 0–17 years and in adult 
patients is presented in Table 1.
iGAS isolates originated from abscesses (47.1%), 
blood culture samples (24.1%), surgical samples (16.7%), 
biopsies (4.6%), pleural fluid (3.5%), pus (2.0%), synovial 
fluid (1.3%) and CSF samples (0.7%). In contrast, iGCGS 
Figure 1 Incidence and rates of pGAS isolates during the study period, 2008–2017.
Figure 2 Incidence and rates of pGCGS isolates during the study period, 
2008–2017.
Figure 3 Incidence and rates of iGAS isolates during the study period, 2008–2017.
Figure 4 Incidence and rates of iGCGS isolates during the study period, 
2008–2017.
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isolates mainly originated from blood culture samples 
(53.8%), abscesses (22.9%), surgical samples (12.3%), 
synovial fluid (5.1%), pleural fluid (3.7%), pus (1.8%) 
and CSF samples (0.4%).
Antibiotic Resistance of GAS/GCGS 
Isolates Throughout the Study Period
The susceptibility-testing results of GAS and GCGS isolates 
over the 10-year study period are presented in Table 2. All 
respective isolates were susceptible to benzyl-penicillin (ie, 
all β-lactam antibiotics), tetracycline (ie, also susceptible to 
doxycycline, minocycline, tigecycline), vancomycin and 
linezolid. Nevertheless, overall resistance levels of erythro-
mycin (10.5% for GAS, 21.4% for GCGS) and clindamycin 
(9.2% for GAS, 17.2% for GCGS) were significantly higher 
in GCGS isolates, while resistance levels for norfloxacin (ie, 
fluoroquinolone antibiotics) were higher in Group A isolates 
(13.5% for GAS, 6.9% for GCGS). There were no statisti-
cally significant differences seen in the resistance levels of 
GAS and GCGS isolates between the 2008–2012 and 
2013–2017 time periods (data not shown).
Discussion
A total of 1554 cases of streptococcal tonsillo-pharyngitis 
and 1104 cases of invasive streptococcal infections were 
noted in Southern Hungary; although the majority of isolates 
still belonged to GAS, the steady increase in the isolation 
rates of GCGS isolates were shown in Southern Hungary, 
which is consistent with the worldwide reports (GCS: 2–7%, 
GGS: 0.1–2.5%), showing an increase in the GCS/GGS- 
related disease burden. Although the incidence of iGCGS 
isolates were proportionally higher in patients aged 18 and 
older, pronounced epidemiological differentiation towards 
adult patients, similar to what has been shown in previous 
reports in the literature; in contrast, this tendency was not 
verified for pGCGS isolates whatsoever. Nonetheless, resis-
tance levels were consistently higher in GCGS isolates (with 
the exception of quinolones), with has been noted in previous 
publications. Although many international studies from the 
last 5–10 years have noted the increase in the isolation 
frequency of GCGS isolates (which occurred from 2013 in 
our local settings), this coincided with the introduction of the 
MALDI-TOF MS in routine diagnostics. It is unclear 
whether this increase reflects true epidemiological changes 
(associated with the ageing population and the higher number 
of patients with risk factors for iCGCS infections) or rather, 
a technical change in diagnostics – which may have also 
distorted the results of other studies reporting an increased 
incidence.4,27,37,38,41 As there are no other reports available 
from the other regions of Hungary, it is also hard to ascertain 
the possible role of a geographical component.
Although the majority of GAS and GCS/GGS isolates 
remain exquisitely sensitive to penicillin in vitro,45 the 
clinical management of severe, invasive β-haemolytic 
streptococcal infections remain challenging.46 While peni-
cillin is still considered as the first-choice drug for uncom-
plicated streptococcal infections, they have been proven 
ineffective in invasive infections.47 In fact, based on the 
recommendations of the Infectious Diseases Society of 
America, penicillin should be used in combination with 
a protein synthesis inhibitor (eg, clindamycin) in these 
clinical cases.48 The use of clindamycin for life- 
threatening invasive infections was shown to reduce mor-
tality rates.49 Patients with penicillin-allergy (where these 
patients may also have cross-reactions with cephalosporins 
and carbapenems) must also be considered during the 
Table 2 Antibiotic Resistance Levels of Group A and Group C/G Streptococcal Infections Causing Pharyngitis and Invasive Infections, 
2008–2017
GAS GCGS Statistics*
pGAS iGAS Overall pGCGS iGCGS Overall
Benzyl-penicillin 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
Erythromycin 146 (9.8%) 100 (11.6%) 246 (10.5%) 15 (21.4%) 52 (21.4%) 67 (21.4%) p<0.0001 (Χ2=31.69, DOF: 1)
Clindamycin 118 (7.9%) 98 (11.4%) 216 (9.2%) 14 (20.0%) 40 (14.6%) 54 (17.2%) p<0.0001 (Χ2=19.56, DOF: 1)
Trimethoprim-sulfamethoxazole 48 (3.2%) 25 (2.9%) 73 (3.1%) 0 (0%) 1 (0.4%) 1 (0.2%) p=0.005 (Χ2=7.96, DOF: 1)
Norfloxacin 199 (13.4%) 117 (13.6%) 316 (13.5%) 4 (5.7%) 13 (7.4%) 17 (6.9%) p<0.0001 (Χ2=16.31, DOF: 1)
Tetracycline 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
Vancomycin 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
Linezolid 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) -
Note: *Statistical comparison of resistance levels among GAS and GCGS isolates overall. 
Abbreviation: DOF, degrees of freedom.
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choice of therapy.50,51 In case of patients with penicillin 
allergy, macrolides, lincosamides and fluoroquinolones are 
considered as relevant therapeutic alternatives.52 However, 
one of the most concerning developments include the 
description of penicillin-resistance in boh GAS53 and 
SDSE54 isolates, linked to a pbp2x mutation; additionally, 
a report provided evidence of a large clonal population of 
GAS with sub-clinical β-lactam tolerance (associated with 
a similar pbp2x mutation) in Iceland.55
Based on the data mentioned above, the relevance of 
protein-synthesis inhibitor antibiotics in the therapy of 
these infections should be stressed further. Increased resis-
tance in GAS and GCS/GGS isolates towards macrolides 
and clindamycin has been reported in many countries, eg, 
macrolide-resistance in GAS was shown to be 22.8% in 
Greece, 32.8% in Spain, 40% in Bulgaria and Belgium and 
may be as high as 95% in China.56 The steady increase in 
resistance was demonstrated in the US, where erythromy-
cin/clindamycin resistance was 14/13% in 2015, 16/15% 
in 2016 and 23/22% in 2017, respectively (based on the 
CDC database). In addition, erythromycin-resistant GAS 
was associated with 5400 cases and 450 extra deaths in 
2017. Macrolide resistance is either mediated by target site 
modification (rRNA methylases; the expression of which 
may be constitutive [cMLS] or inducible [iMLS]) or the 
overexpression of efflux pumps (mefA gene) and is related 
to the M phenotype.56,57 Currently, emm cluster typing 
(which groups emm types into 48 different clusters on 
the basis of their structural properties of the 
M protein).58 Similar to the emergence of fluoroquinolone- 
resistant S. pneumoniae, resistant GAS isolates are also 
increasingly reported; the main mechanism associated with 
these isolates are the mutations of gyrA and parC genes.59 
The emergence of resistance in GAS has been associated 
with the extensive use of relevant antibiotics in the 
country.60 When it comes to antibiotic consumption, 
Hungary is among the countries with low consumption 
levels quantitatively; however, consumption levels of 
macrolides, lincosamides and streptogramins (J01F; 2.8 
defined daily doses/1000 inhabitants per day) and quino-
lones (J01M; 2.3 defined daily doses/1000 inhabitants 
per day) in the country is among the highest in Europe.61 
This phenomenon may explain the rate of resistance in 
Southern Hungary in GAS and GCS/GGS isolates.
In the following section, a concise summary of the most 
relevant epidemiological studies will be presented to put our 
results in context with findings in the international literature. 
In a study by Ekelund et al in Denmark, GAS infections 
were the most numerous (40%) among invasive infections 
between 1999 and 2002, followed by GGS (32%), GBS 
(23%) and GCS (6%). The overall mortality in this study 
was 21%, with most of the GCS/GGS affecting patients 
(74%) with predisposing factors.37 Later on, a nationwide 
study by Lambertsen et al between 2005 and 2011 pointed 
out the increase in the incidence of laboratory-confirmed 
GAS, GBS, GCS and GGS infections (3.1, 2.3, 0.9 and 
2.6 per 100 000 persons, respectively), compared to the 
previous study.62 Zaoutis et al reported the incidence of 
GCS/GGS in acute pharyngitis over a 12-month period in 
Philadelphia, USA: 17.7% of pharyngitis cases were non- 
GAS, and the average age of patients was 6 years.63 In 
a prospective study by Steer et al, the epidemiology of 
invasive GAS over a 2-year period in Fiji was assessed; all- 
age incidence was 9.9 cases/100,000 population per year, 
while the case-fatality rate was 32.0%. In addition, they 
have shown that invasive GAS infections were the most 
common in patients over 65 years of age.5 In a Spanish 
study by Montes et al, the prevalence of GAS isolates was 
studied during 1998–2009;64 incidence of invasive disease 
was 3.1 for children and 1.9 for adults per 100,000 inhabi-
tants, and 17%, 8.9% and 13% of isolates were resistant to 
erythromycin, ciprofloxacin and tetracycline, respectively.64 
Invasive GAS infections were assessed in Germany 
between 2003 and 2007 by Imöhl et al;65 out of n=586 
isolates, susceptibility to penicillin G and levofloxacin was 
100%, while resistance to tetracycline, clarithromycin and 
clindamycin was 11.6%, 5.5% and 1.2%. Clinical manifes-
tations included sepsis (40.1%), necrotizing fasciitis 
(20.8%) and streptococcal toxic shock syndrome 
(16.6%).65 Darenberg et al provided epidemiological results 
for invasive GAS infections for Sweden corresponding to 
2002–2004.66 The incidence was 3.0 cases per 100,000 
population, 11% of the patients developed TSS, while 
9.5% developed necrotizing fasciitis; the overall mortality 
rate was 14.5%. Ho et al assessed the resistance levels of 
invasive and non-invasive GAS isolates between 1995 and 
1998;67 resistance levels to erythromycin and tetracycline 
were high (32% and 53%). Rantala et al provided 
a population-based study, corresponding to the period 
between 1995 and 2004, during which 18 cases of GCS 
and 128 GGS bacteremia were identified.68
Harris et al carried out a 14-year-long study in Australia, 
assessing bacteraemia caused by beta-haemolytic strepto-
cocci: GAS isolates were the most common (49%), with 
GCS/GGS isolates showing a modest, but significant, 
increase over time. Significant differences were no observed 
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in the mortality rates between the different beta-haemolytic 
streptococci infections.69 Wong et al reported n=73 invasive 
GGS infections in a New York community hospital over 
a 5-year period; the mean age of patients was 53 years, and 
the average length of stay for all patients with GGS was 9.4 
days, with longer stays for those with underlying diabetes 
mellitus (14.6 days).70 Bruun et al studied the incidence of 
GCS/GGS necrotizing soft tissue infections in Norway 
(2000–2009):71 they have reported a mean annual incidence 
rate of 1.4 per 100 000, with a mortality rate of 33%, 
compared to 11% in the GAS group. Hashikawa et al char-
acterized GCS/GGS causing toxic shock syndrome (STSS) 
in Japan, finding that all STSS-causing isolates had a close 
genetic relationship.72 Slyvetsky et al showed that 15% of 
bacteremia caused by β-hemolytic Streptococcus was GGS, 
with a mortality rate of 15%.35 Loubinoux et al character-
ized n=182 isolates of SDSE from invasive and non- 
invasive infections between 2006 and 2010; resistance to 
macrolides was 26.4%, while resistance to tetracycline was 
34.6%.73
During a 15-year-long surveillance period, Oppegaard 
et al38 assessed the incidence of invasive and non-invasive 
GAS, GCS and GGS isolates in Western Norway: the 
distribution of invasive isolates was 58% GAS, 5% GCS 
and 37% GGS, respectively. The incidence of all isolates 
increased with patient age, a male dominance was 
observed, and a seasonal variation was shown, similarly 
to our study. The incidence of invasive GCGS infections 
increased from 1.4 to 6.3 per 100,000 persons from the 
beginning to the end of the study period, while GAS infec-
tions showed marked fluctuations (2.7–8.3 per 100,000 -
persons).38 As a part of the Arctic Investigations Program 
(AIP), Rudolph et al surveyed the incidence of invasive 
GAS infections in Alaska between 2001 and 2013.41 
Resistance to tetracycline, erythromycin, and clindamycin 
were relatively low (11.0%, 5.8% and 1.2%, respectively) 
with an observed incidence of 5.8 cases per 100,000 per-
sons; the mortality rate was 10.7%, overall. In a large 
collaborative study (by the Strep-EURO Study Group) 
involving 11 European countries, the emergence of severe 
S. pyogenes infections was surveyed between 2003 and 
2004;74 the reported incidence was 3/100,000 population, 
which higher incidences in the northern European coun-
tries, while the 7-day mortality rate was 19% (44% for 
patients with STSS). This European study has also high-
lighted the seasonal variation in invasive GAS infections, 
which coincided in almost all participating countries. The 
epidemiology of invasive GAS infections was assessed on 
a national level by the CDC: between 2000 and 2004, the 
incidence was 3.5 cases/100,000 persons with an overall 
mortality rate of 13.7% (36.0% for STSS and 24.0% for 
necrotizing fasciitis).75 The continuation of this study in 
2005–2012 saw a slight increase in overall incidence (3.8 
cases/100,000 persons) and a decrease in mortality rate 
(11.7%; mortality rate in patients aged 65 and over: 9.4/ 
100 000).76 M typing and the molecular characterization of 
resistance-determinants in a national setting has important 
public health implications; nevertheless, there is a scarcity 
of data on the molecular epidemiology of streptococci in 
Hungary. This scarcity was not improved by the fact that 
Hungary was not among the participating members of the 
Strep-EURO group study.77 The most recent data available 
are from the early 2000s: Gattringer et al characterized 
n=191 S. pyogenes isolates originating from Hungary. In 
their report, 3.7% of the isolates were resistant to macro-
lides (mainly due to mefA and ermTR genes) and 30.5% 
were resistant to tetracycline (the large volume of prophy-
lactic tetracycline use may have contributed to this rate).78 
Additionally, Krucsó et al characterized n=26 invasive 
GAS isolates from Hungary with molecular biological 
methods during 2004–2005: the following emm types 
were the most numerous: emm1 (50%), emm80 (19.2%); 
however, other M types were also described in these iso-
lates (emm4, emm28, emm66, emm81.1, emm82 and 
emm84).79
Limitations of the Study
Some limitation of our study should be addressed: i) the 
study design is retrospective and there was scarce clinical 
data available due to the inability to access the medical 
records of the individual patients. ii) for this reason, the 
association of relevant risk factors, underlying illnesses 
(apart from age and inpatient/outpatient status) and studies 
infections could not be performed (however, attempts were 
made to discard/exclude isolates with little or no clinical 
relevance). iii) our study is subject of selection bias, ie, it 
reports the results from a tertiary-care hospital, corre-
sponding to patients with more severe conditions or under-
lying illnesses. iv) the CDC has recently identified SDSE 
isolates containing Group A antigens; as the uncertainty of 
misidentification regarding the presence of such isolates 
could not be excluded using our methods, this must also be 
noted as a limitation. v) data on emm typing or M typing 
could have strengthened the relevance of our results in an 
international context; however, due to the prolonged study 
period, lacking technical capabilities, monetary constraints 
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and the overwhelming number of isolates to be tested, our 
study did not include this. vi) the molecular characteriza-
tion of resistance determinants (eg, macrolide, quinolone 
resistance) in the individual isolates and erm typing were 
not performed as a part of this study for reasons mentioned 
in point v).
Conclusions
In our study, the epidemiology and resistance levels were 
assessed among Groups A, C and G β-haemolytic strepto-
cocci in Southern Hungary, over a long surveillance per-
iod. While there was undoubtedly an increase in the 
isolation rate of GCGS isolates, associations with patients 
characteristics are still unclear. The rates of resistance to 
macrolides and clindamycin are a cause for concern (espe-
cially among GCGS isolates); however, resistance levels 
are still relatively low, compared to Southern European 
countries. Due to the constant burden of β-haemolytic 
streptococcal diseases, the continuous surveillance of 
GAS and GCGS infections in both tonsillo-pharyngitis 
and in invasive infections is warranted.
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